Gambro Expands In The USA
The Swedish company Gambro is to acquire the remaining stock it does not already hold of Ren Corporation of the USA through its US affiliate, Cobe Corporation. Gambro is offering $18 per share or $170 million for the company. Cobe Laboratories already holds around 53% of Ren's common stock.
Gambro's offer represents a premium of around 18% on the average closing price of Ren common stock over the 60 days of trading ended July 12, according to Gambro.
Deal Will Improve Growth Conditions "With Ren as a wholly-owned subsidiary, growth conditions for Cobe and Ren will be very much improved," according to Berthold Lindqvist, chief executive of Gambro. He added: "the Gambro group and Cobe will be better-positioned to compete successfully in the US market, where increased consolidation of health care organizations is a typical feature."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze